Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ:REGN) announced on Monday that it has successfully completed the acquisition of Decibel Therapeutics, Inc., a move that strengthens...
Regeneron (NASDAQ:REGN) Pharmaceuticals has recently experienced a boost in its future growth prospects, following a period of declining growth rate. The company's revenue had surged from $2...
AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing multi-target collaboration with Regeneron (Nasdaq: NASDAQ:REGN) to discover therapeutic antibodies for up to eight...
New York, USA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Diffuse Large B-cell Lymphoma Market to Show Immense Growth by 2032, Predicts DelveInsight | Leading Players to Look Out - AbbVie,...
An analyst from WestPark Capital initiated coverage of Regeneron Pharma (NASDAQ: REGN) at 'hold' . Prior to this rating, Regeneron Pharma had 16 buy ratings, 7 hold ratings, and 1 sell...
Regeneron (NASDAQ:REGN) Pharmaceuticals is set to sell a potential COVID-19 prophylactic antibody in the U.S. at an internationally comparable price, according to a recent update on its deal...
Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ: REGN) unveiled a series of leadership changes on Friday, including a transition at the Chief Financial Officer (CFO) level and updates...
Regeneron Pharmaceuticals, Inc. (REGN) today announced that Robert E. Landry, Executive Vice President, Finance and Chief Financial Officer of Regeneron, will retire in February 2024....
Regeneron Pharmaceuticals, Inc. (REGN) today announced that Kathryn Guarini, Ph.D., and David P. Schenkein, M.D., have joined Regeneron’s Board of Directors effective September 8,...
Regeneron Pharmaceuticals Inc. REGN said late Friday that Chief Financial Officer Robert E. Landry will retire in February, and Christopher Fenimore, the pharma company’s current head of...
Celularity Inc (NASDAQ: CELU) shares are trading higher after the company announced a multi-year Research Collaboration Services Agreement with Regeneron Pharmaceuticals Inc (NASDAQ:...
Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (REGN) today announced that the Biomedical Advanced Research and Development Authority (BARDA) has entered into an agreement with Regeneron to...
Friday, the FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration, diabetic macular edema, and...
An analyst from Canaccord Genuity upgraded Regeneron Pharma (NASDAQ: REGN) from 'hold' to 'buy' with a price target of $992.00. Prior to this rating, Regeneron Pharma had 15 buy ratings, 8...
Shares of Regeneron (NASDAQ:REGN) gained over 1% in pre-open trading Monday after the FDA on Friday approved EYLEA HD Injection 8 mg for the treatment of patients with wet age-related...
An analyst from Wells Fargo maintained Regeneron Pharma (NASDAQ: REGN) at 'overweight' with a price target of $980.00 from a prior price target of %currency%%price%. Prior to this rating,...
An analyst from RBC Capital maintained Regeneron Pharma (NASDAQ: REGN) at 'sector perform' with a price target of $830.00 from a prior price target of %currency%%price%. Prior to this...
An analyst from Oppenheimer maintained Regeneron Pharma (NASDAQ: REGN) at 'outperform' with a price target of $1050.00 from a prior price target of %currency%%price%. Prior to this rating,...
An analyst from BMO Capital maintained Regeneron Pharma (NASDAQ: REGN) at 'outperform' with a price target of $985.00 from a prior price target of %currency%%price%. Prior to this rating,...
An analyst from Barclays maintained Regeneron Pharma (NASDAQ: REGN) at 'overweight' with a price target of $925.00 from a prior price target of %currency%%price%. Prior to this rating,...
Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (REGN) today announced the U.S. Food and Drug Administration (FDA) has approved Veopoz™ (pozelimab-bbfg) for the treatment of adult and...
Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (REGN) today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for...
By Davit KirakosyanHere is your Pro Recap of 4 head-turning deal dispatches you may have missed this week: Deals at |Capri-Tapestry, Decibel-Regeneron, Amazon in talks to potentially anchor...
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced two-year (96 weeks) topline data from the pivotal PULSAR trial investigating aflibercept 8 mg in patients with wet age-related macular...
Decibel Therapeutics Inc. DBTX stock was up 85% in premarket trades on Wednesday after Regeneron Pharmaceuticals Inc. REGN said it would pay $4 a share for the Boston-based clinical-stage...
Regeneron Pharmaceuticals Inc. REGN said Wednesday it would pay $4 a share for Decibel Therapeutics Inc. DBTX, a 43% premium over its closing price of $2.79 a share in the previous session....
An analyst from UBS maintained Regeneron Pharma (NASDAQ: REGN) at 'buy' with a price target of $895.00 from a prior price target of %currency%%price%. Prior to this rating, Regeneron...
An analyst from Morgan Stanley maintained Regeneron Pharma (NASDAQ: REGN) at 'overweight' with a price target of $912.00 from a prior price target of %currency%%price%. Prior to this...
An analyst from Oppenheimer maintained Regeneron Pharma (NASDAQ: REGN) at 'outperform' with a price target of $950.00 from a prior price target of %currency%%price%. Prior to this rating,...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
